glp-1 pancreatitis risk of pancreatic cancer associated with receptor agonist therapy GLP-1 Use After Pancreatitis: Provider
Description
pmid:23615264 50
Mijit, A
Ozempic and Zepbound are popular options for weight loss management, but they work in different ways
VESPER-3 VESPER-3 was a 64-week placebo-controlled trial that assessed the efficacy and safety of monthly berobenatide in adults with obesity or overweight with hypertension and/or dyslipidemia
placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial
